Real-world evidence on the economic implications of CGRP inhibitors as preventive treatment of migraine in Denmark

Migraine is a serious condition with large implications for patients. Some patients with severe migraine can receive preventive treatment with CGRP inhibitors, but the economic implications of the treatment from a societal perspective have been unclear.

In this study, we estimate the total societal gain from initiating treatment with CGRP inhibitors in patients with chronic and episodic migraine in Denmark. To do so, we collected novel real-world data on Danish patients with at least four monthly migraine days.

The main conclusions of our study are

The study is commissioned by Novartis Healthcare A/S.

The economic model is published in a BMC Neurology, see Siersbæk, N., Kilsdal, L., Jervelund, C., Antic, S., & Bendtsen, L. (2023). Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine. BMC Neurology, 23(1), 1-11.